Cytek Biosciences Inc (CTKB)
Cytek Biosciences Inc is a healthcare company focused on cell analysis solutions for biomedical research and clinical applications. The company develops and markets flow cytometry and image-based flow cytometry instruments, including the Cytek Aurora, Northern Lights, and Aurora Evo systems, along with the Aurora CS system, Amnis ImageStream imaging flow cytometers, Guava Muse cell analyzers, Guava easyCyte flow cytometers, and Orion reagent cocktail preparation systems. Its product range also includes cFluor reagents and kits, automated sample-loading and micro-sampling systems, SpectroFlo software, and related customer support tools. Cytek Biosciences serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes products through direct sales and support teams in North America, Europe, China, and the Asia-Pacific region, as well as through distributors and sales agents in parts of Europe, Latin America, and the Middle East. The company was founded in 1992 and is headquartered in Fremont, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CTKB
|
$5.14
|
14.9% Upside
|
Fair
|
$5.69
|
27.2% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-7.9x
|
1.8x
|
2.8x
|
591.5 M
|
346.4 M
|
4.4%
|
74.8%
|
3.5
|
—
|
17.2%
|